

Highlights of This Issue 3705**SPECIAL FEATURES****CCR Translations****3707** Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia

Eric Solary

*See related article, p. 3746***3710** Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon

Nicole G. Chau and Peter S. Hammerman

*See related article p. 3961***CCR Drug Updates****3713** Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer

Daniel Morgensztern and Roy S. Herbst

Molecular Pathways**3718** Molecular Pathways: Endothelial Cell FAK—A Target for Cancer Treatment

Marina Roy-Luzarraga and Kairbaan Hodivala-Dilke

Review**3725** Cancer Tills the Premetastatic Field: Mechanistic Basis and Clinical Implications

Andrew R. Chin and Shizhen Emily Wang

CANCER THERAPY: CLINICAL**3734** Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

Rikke Andersen, Marco Donia, Eva Ellebaek, Troels Holz Borch, Per Kongsted, Trine Zeeberg Iversen, Lisbet Rosenkrantz Hölmich, Helle Westergren Hendel, Özcan Met, Mads Hald Andersen, Per thor Straten, and Inge Marie Svane

3746 A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, and Rami S. Komrokji on behalf of the Myelodysplastic Syndrome Clinical Research Consortium

*See related commentary, p. 3707***3755** Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna K. Samant, Steve Olsen, Sanne L. de Haas, and Mark D. Pegram

3764 Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid, Bryan Hennessy, Gordon B. Mills, Kristin C. Jensen, Zoltan Szallasi, William T. Barry, Eric P. Winer, Nadine M. Tung, Steven J. Isakoff, Paula D. Ryan, April Greene-Colozzi, Alexander Gutin, Zaina Sangale, Diana Iliev, Chris Neff, Victor Abkevich, Joshua T. Jones, Jerry S. Lanchbury, Anne-Renee Hartman, Judy E. Garber, James M. Ford, Daniel P. Silver, and Andrea L. Richardson

3774 Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer

Michael J. Morris, Dana E. Rathkopf, William Novotny, Jacqueline A. Gibbons, Amy C. Peterson, Zakaria Khondker, Taoufik Ouatas, Howard I. Scher, and Mark T. Fleming

3782 A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Pedro C. Rodriguez, Xitllaly Popa, Odeth Martínez, Silvia Mendoza, Eduardo Santiesteban, Tatiana Crespo, Rosa M. Amador, Ricardo Fleytas, Soraida C. Acosta, Yanine Otero, Gala N. Romero, Ana de la Torre, Mireysi Cala, Lina Arzuaga, Loisel Vello, Delmairis Reyes, Niurka Futiel, Teresa Sabates, Mauricio Catala, Yoanna I. Flores, Beatriz Garcia, Carmen Viada, Patricia Lorenzo-Luaces, Maria A. Marrero, Liuba Alonso, Jenelin Parra, Nadia Aguilera, Yaisel Pomares, Patricia Sierra, Gryssell Rodríguez, Zaima Mazorra, Agustin Lage, Tania Crombet, and Elia Neninger

Table of Contents

3791 Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN α Combined with Chemotherapy

Daniel H. Serman, Evan Alley, James P. Stevenson, Joseph Friedberg, Susan Metzger, Adri Recio, Edmund K. Moon, Andrew R. Haas, Anil Vachani, Sharyn I. Katz, Jing Sun, Daniel F. Heitjan, Wei-Ting Hwang, Leslie Litzky, Jennifer H. Yearley, Kay See Tan, Emmanouil Papasavvas, Paul Kennedy, Luis J. Montaner, Keith A. Cengel, Charles B. Simone II, Melissa Culligan, Corey J. Langer, and Steven M. Albelda

PERSONALIZED MEDICINE AND IMAGING

3801 Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma

Anne-Ségolène Cottreau, Hélène Lanic, Sylvain Mareschal, Michel Meignan, Pierre Vera, Hervé Tilly, Fabrice Jardin, and Stéphanie Becker

3810 MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer:



A Report from the Center for Cancer Research
Wendy Chang, Andrew S. Brohl, Rajesh Patidar, Sivasish Sindiri, Jack F. Shern, Jun S. Wei, Young K. Song, Marielle E. Yohe, Berkley Gryder, Shile Zhang, Kathleen A. Calzone, Nityashree Shivaprasad, Xinyu Wen, Thomas C. Badgett, Markku Miettinen, Kip R. Hartman, James C. League-Pascual, Toby N. Trahair, Brigitte C. Widemann, Melinda S. Merchant, Rosandra N. Kaplan, Jimmy C. Lin, and Javed Khan

3821 Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer

Haiming Luo, Christopher G. England, Sixiang Shi, Stephen A. Graves, Reinier Hernandez, Bai Liu, Charles P. Theuer, Hing C. Wong, Robert J. Nickles, and Weibo Cai

3831 Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

Evgeny Yakirevich, Murray B. Resnick, Shamlal Mangray, Michael Wheeler, Cynthia L. Jackson, Kara A. Lombardo, Jeeyun Lee, Kyoung-Mee Kim, Anthony J. Gill, Kai Wang, Kyle Gowen, James Sun, Vincent A. Miller, Philip J. Stephens, Siraj M. Ali, Jeffrey S. Ross, and Howard Safran

3841 MicroRNA *MIR21* (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival

Kosuke Mima, Reiko Nishihara, Juhong Yang, Ruoxu Dou, Yohei Masugi, Yan Shi, Annacarolina da Silva, Yin Cao, Mingyang Song, Jonathan Nowak, Mancang Gu, Wanwan Li, Tepei Morikawa, Xuehong Zhang, Kana Wu, Hideo Baba, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Andrew T. Chan, Charles S. Fuchs, Zhi Rong Qian, and Shuji Ogino

CANCER THERAPY: PRECLINICAL

3849 Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma



Yumeng Mao, Nina Eissler, Katarina Le Blanc, John Inge Johnsen, Per Kogner, and Rolf Kiessling

3860 Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma



Xueqing Lun, J. Connor Wells, Natalie Grinshtein, Jennifer C. King, Xiaoguang Hao, Ngoc-Ha Dang, Xiuling Wang, Ahmed Aman, David Uehling, Alessandro Datti, Jeffrey L. Wrana, Jacob C. Easaw, Artee Luchman, Samuel Weiss, J. Gregory Cairncross, David R. Kaplan, Stephen M. Robbins, and Donna L. Senger

3876 Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 *In Vivo*

Denada Dibra, Abhisek Mitra, Melisa Newman, Xueqing Xia, Jeffrey J. Cutrera, Mihai Gagea, Eugenie S. Kleinerman, Guillermina Lozano, and Shulin Li

3884 FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

Koos Koole, Diede Brunen, Pauline M.W. van Kempen, Rob Noorlag, Remco de Bree, Cor Liefink, Robert J.J. van Es, René Bernards, and Stefan M. Willems

3894 Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Keith W. Pratz, Brian D. Koh, Anand G. Patel, Karen S. Flatten, Weijie Poh, James G. Herman, Robert Dilley, Maria I. Harrell, B. Douglas Smith, Judith E. Karp, Elizabeth M. Swisher, Michael A. McDevitt, and Scott H. Kaufmann

Table of Contents

3903 DiSCoVErING Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with *In Silico* Analysis to Identify Novel Therapeutic Targets

Allison R. Hanaford, Tenley C. Archer, Antoinette Price, Ulf D. Kahlert, Jarek Maciaczyk, Guido Nikkhah, Jong Wook Kim, Tobias Ehrenberger, Paul A. Clemons, Vlado Dančík, Brinton Seashore-Ludlow, Vasanthi Viswanathan, Michelle L. Stewart, Matthew G. Rees, Alykhan Shamji, Stuart Schreiber, Ernest Fraenkel, Scott L. Pomeroy, Jill P. Mesirov, Pablo Tamayo, Charles G. Eberhart, and Eric H. Raabe

BIOLOGY OF HUMAN TUMORS

3915 PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

Jason Madore, Dario Strbenac, Ricardo Vilain, Alexander M. Menzies, Jeen Y. H. Yang, John F. Thompson, Georgina V. Long, Graham J. Mann, Richard A. Scolyer, and James S. Wilmott

3924 Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

Carlos Alfaro, Alvaro Teijeira, Carmen Oñate, Guiomar Pérez, Miguel F. Sanmamed, María Pilar Andueza, Diego Alignani, Sara Labiano, Arantza Azpilikueta, Alfonso Rodríguez-Paulete, Saray Garasa, Juan P. Fusco, Angela Aznar, Susana Inogés, María De Pizzol, Marcello Allegretti, Jose Medina-Echeverz, Pedro Berraondo, Jose L. Perez-Gracia, and Ignacio Melero

3937 Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression



Sandra M. Lopez, Alexander I. Agoulnik, Manqi Zhang, Leif E. Peterson, Eglá Suarez, Gregory A. Gandarillas, Anna Frolov, Rile Li, Kimal Rajapakshe, Christian Coarfa, Michael M. Ittmann, Nancy L. Weigel, and Irina U. Agoulnik

3950 FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the *c-Myc*/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer



Shunrong Ji, Yi Qin, Chen Liang, Run Huang, Si Shi, Jiang Liu, Kaizhou Jin, Dingkong Liang, Wenyan Xu, Bo Zhang, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Paul J. Chiao, Min Li, and Xianjun Yu

3961 Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab



Paolo Bossi, Cristiana Bergamini, Marco Siano, Maria Cossu Rocca, Andrea P. Sponghini, Federica Favales, Marco Giannoccaro, Edoardo Marchesi, Barbara Cortelazzi, Federica Perrone, Silvana Pilotti, Laura D. Locati, Lisa Licitra, Silvana Canevari, and Loris De Cecco

See related commentary, p. 3710

3971 Effectiveness of Prophylactic Surgeries in *BRCA1* or *BRCA2* Mutation Carriers: A Meta-analysis and Systematic Review



Xiao Li, Ran You, Xinwei Wang, Congxin Liu, Zicheng Xu, Jin Zhou, Bin Yu, Ting Xu, Hongzhou Cai, and Qing Zou

CORRECTIONS

3982 Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by *TP53* Mutation in Preclinical Models of Colorectal Cancer

3983 Correction: Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study

3984 Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma

AC icon indicates Author Choice


CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows Fluor-18-deoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scans of a patient with two metastatic lesions in the right lung. The image shows increased FDG uptake in the lesions prior to adoptive cell transfer therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL). For details, see the article by Andersen and colleagues on page 3734 of this issue.



Clinical Cancer Research

22 (15)

Clin Cancer Res 2016;22:3705-3984.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/15>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/15>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.